A Phase 1/2, First-in-Human, Multicenter, Open-Label Study of SQZ-eAPC-HPV as Monotherapy and in Combination with Immune Checkpoint Inhibitor(s) in Patients with HPV16+ Recurrent, Locally Advanced, or Metastatic Solid Tumors
|Effective start/end date||11/23/22 → 11/23/27|
- SQZ BIOTECHNOLOGIES COMPANY
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.